Piper Sandler Raises IDEXX Laboratories (IDXX) PT to $700, Cites Strong Q2 Results

IDEXX Laboratories Inc. (NASDAQ:IDXX) is one of the best performing S&P 500 stocks to buy now. On August 11, Piper Sandler raised the firm’s price target on Idexx Laboratories to $700 from $510 following the company’s Q2 2025 financial results. The firm kept a Neutral rating on the shares.

IDEXX Laboratories reported total revenues of $1,109 million in Q2, which was an increase of 11% as reported and 9% organically, compared to the prior year. This was driven by a strong performance from its Companion Animal Group/CAG and Water segments, which saw revenue increases of 11% and 9% as reported, respectively.

Within the Companion Animal Group, IDEXX VetLab consumables revenue grew by 15% as reported and 14% organically. The company also saw a 66% reported increase in CAG Diagnostics capital instrument revenues, driven by record placements of its new IDEXX InVue Dx instrument. Rapid assay products revenues, however, declined by 3% as both reported and organic, as some testing shifted to new modalities.

IDEXX Laboratories Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the US and internationally.

While we acknowledge the potential of IDXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.